Arcutis Biotherapeutics, Inc.
ARQTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $372.1M | $166.5M | $29.2M | $3.7M | $0 | $0 |
| Operating income | −$12.2M | −$128.4M | −$241.1M | −$301.6M | −$206.5M | −$136.6M |
| Net income | −$16.1M | −$140.0M | −$262.1M | −$311.5M | −$206.4M | −$135.7M |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M | $298.3M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M | $27.6M |
| Equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M | $270.6M |
| EPS (diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 |
| Shares out. | 118.6M | 96.8M | 61.1M | 50.4M | 50.1M | 43.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −3.3%
- Net margin
- −4.3%
- Return on equity
- −8.5%
- Return on assets
- −3.7%
- Return on capital (ROCE)
- −4.0%
- Liabilities / assets
- 56.2%
- Debt / equity
- 1.29×
- Book value / share
- $1.60
- Revenue growth (YoY)
- 123.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -3.68distress
- Accruals / assets
- −2.4%clean
- Beneish M-Score
- -1.38elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- State Street CorpPassive (13G)May 12, 2026
- Prudential Financial IncPassive (13G)May 8, 2026
- Jennison Associates LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Rubric Capital Management LpPassive (13G)Feb 13, 2026
- Frazier Life Sciences Viii, L.P.Activist (13D)Aug 20, 2025
- Polar Capital Holdings PlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 17.5M | 7.3 | +4.0% |
| Apr 30, 2026 | 16.9M | 16.6 | +1.8% |
| Apr 15, 2026 | 16.6M | 15.6 | -1.3% |
| Mar 31, 2026 | 16.8M | 11.1 | +6.7% |
| Mar 13, 2026 | 15.8M | 12.6 | +3.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsFeb 25, 2026
- Director / officer change · Regulation FD disclosureDec 8, 2025
- Results of operationsOct 28, 2025
- Results of operationsAug 6, 2025
- Shareholder vote · Other material eventJun 17, 2025
- Results of operationsMay 6, 2025
- Director / officer change · Regulation FD disclosureApr 10, 2025
- Results of operationsFeb 25, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4FORM 4May 13, 2026
- 4FORM 4May 13, 2026
- SCHEDULE 13GMay 12, 2026
- 144May 11, 2026
- 144May 11, 2026
- SCHEDULE 13G/AMay 8, 2026
- 4FORM 4May 6, 2026
- 4FORM 4May 6, 2026
- 4FORM 4May 6, 2026
- 4FORM 4May 6, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- 4FORM 4May 5, 2026
- 144May 4, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.